Directory board

Emmanuel ScotetEmmanuel Scotet
Director of Labex IGO
UMR 1232 Center for Research in Cancerology and Immunology Nantes / Angers
emmanuel.scotet@inserm.fr
Regis JosienRegis Josien
Deputy Director of Labex IGO

UMR 1064 Center for Research in Transplantation and Immunology
regis.josien@inserm.fr

Steering Committee

Patricia Ame-Thomas
INSERM UMR 1236 - MICMAC
patricia.ame@univ-rennes1.fr
 
Laetitia Gautreau
INSERM UMR 1232 Center for Research in Cancerology and Immunology Nantes / Angers
laetitia.gautreau@univ-nantes.fr
 
Sophie Brouard
INSERM UMR 1064 Center for Research in Transplantation and Immunology
sophie.brouard@univ-nantes.fr
 
Carole Guillonneau
INSERM UMR 1064 Center for Research in Transplantation and Immunology
carole.guillonneau@univ-nantes.fr
 
Pierre-François Cartron
INSERM UMR 1232 Center for Research in Cancerology and Immunology Nantes / Angers
Pierre-francois.cartron@inserm.fr
 
Nathalie Labarrière
INSERM UMR 1232 Center for Research in Cancerology and Immunology Nantes / Angers
nathalie.labarriere@univ-nantes.fr
 
Nicolas Degauque
INSERM UMR 1064 Center for Research in Transplantation and Immunology
nicolas.degauque@inserm.fr
 
Jacques-Olivier Pers
INSERM UMR 1227 B lymphocytes and autoimmunity
pers@univ-brest.fr
 
Ghislaine Duisit
Atlanpole Biotherapies
duisit@atlanpole.fr
 

Scientific Committee


Marc Bonneville
Marc BonnevilleMarc Bonneville started to work in 1983 on transplantation immunology in Nantes (France), and then switched from 1987 to 1989 to upstream immunological issues dealing with mouse cellular immune responses during his postdoctoral training in S. Tonegawa’s laboratory (MIT, Boston). Since 1990 he has been heading a research group working on human cellular immune responses in various physiopathological contexts, with a main focus on so-called « transitional immunity » mediated by gd and NKT cells on the one hand, and virus-specific conventional T cell responses on the other hand. Together with 5 other scientists, he founded in 1999 a biotech company (Innate Pharma SA) that has been developing new immunotherapeutic approaches targeting innate lymphocytes (gd T and NK cells) in the field of infectiology and oncology. Marc Bonneville has authored around 200 scientific papers and 8 patents. He has received several awards and prizes (Bronze and Silver CNRS medal, Halpern and LNCC prizes, …). He has been involved in more than 20 scientific councils and committees and has been an advisor of the INSERM General Director in the field of immunology and biotherapies from 2000 to 2007. As of October 2013, Marc Bonneville has taken up the position of vice-president in charge of the scientific and medical affairs of Institut Merieux, a company dedicated to the development of diagnostic and therapeutic tools in the fields of infectious diseases, cancer and food safety.


Paolo Dellabona
Paolo DellabonaPaolo Dellabona graduated in medicine and obtained a Ph.D. in medical genetics from the University of Torino. He is currently joint-head with Giulia Casorati of the Experimental Immunology Unit and Coordinator of the Program of Cancer Immunology and Immuno-Biotherapy at the San Raffaele Scientific Institute in Milano. His main scientific interest concerns the understanding of the development and anti-tumor functions of CD1-restricted T lymphocytes, with a particular focus on NKT cells, a subset of T lymphocytes displaying innate effector functions.


Renato Monteiro
RenatoMonteiroRenato  Monteiro  is  professor  of  Immunology  at  Paris  Diderot  University  and  head  of  the   Center  for  Research  on  Inflammation  –  INSERM  U1149  &  CNRS  ERL8252  located  at  Bichat   Hospital  campus  in  Paris.  After  obtaining  his  medical  degree  in  Brazil  and  then  completing   a  residency  in  nephrology,  he  moved  to  Paris  in  1982  to  study  nephrology  at  the  Necker   Hospital  under  the  mentoring  of  Professor  Jean  Berger.  Prof.  Monteiro  was  awarded  the   1986  Prize  of  the  French  Society  of  Nephrology  for  his  work  on  IgA  nephropathy,  notably   for  the  identification  of  abnormal  IgA  in  Berger’s  disease.  He  later  studied  immunology  at   the  University  of  Birmingham  in  Alabama  with  Professor  Max  Cooper.  Prof.  Monteiro’s   work  in  Prof.  Cooper’s  lab  led  to  the  identification  of  the  IgA  Fc  receptor  I  (CD89).  He   defended  his  PhD  thesis  in  immunology  in  1993  at  Paris  Diderot  University.


Barbara Seliger
Barbara SeligerProfessor Dr. Barbara Seliger is the Director of the Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, in Halle, Germany, Director of a FOCIS Center of Excellence, member of the World Immunoscore and SITC biomarker initiatives. In addition she is head of the work group for “Tumor immunology” of the German Society of Immunology. Prof. Seliger’s research team studies the molecular events associated with immune escape of tumors, the role of the tumor micro-environment and immune cell subpopulations for tumor development and therapy resistance. In addi-tion, her laboratory is involved in optimization and monitoring immunotherapies and in the characteri-zation of biomarkers allowing the prediction of their success. Recently, she became interested in the identification, functional characterization and clinical relevance of immune regulatory microRNAs and RNA-binding proteins as their implementation as therapeutic tools as well as in the role of the tumor and immune cell metabolism in immune surveillance and its modulation as novel therapeutic option alone or in combination with targeted or immunotherapies.


Megan Sykes
Megan SykesDr. Sykes joined Columbia University in April, 2010 after spending 19 years at Massachusetts General Hospital/Harvard Medical School, where she was the Harold and Ellen Danser Professor of Surgery and Professor of Medicine (Immunology). Dr. Sykes’ research career, during which she has published 388 papers and book chapters, has been in the areas of hematopoietic cell transplantation, achievement of graft-versus-leukemia effects without GVHD, organ allograft tolerance induction and xenotransplantation. Dr. Sykes has developed novel strategies for achieving graft-versus-tumor effects without graft-versus-host disease following hematopoietic cell transplantation (HCT). She developed an approach that has been evaluated in clinical trials of non-myeloablative haploidentical HCT whose safety and efficacy allowed trials of HCT for the induction of organ allograft tolerance, with the first intentional achievements of this outcome. Dr. Sykes has dissected the tolerance mechanisms and pioneered minimal conditioning approaches for using HCT to achieve allograft and xenograft tolerance and to reverse the autoimmunity of Type 1 diabetes.


Hans-Dieter Volk
Hans-Dieter VolkHans-Dieter Volk is the Director of the Inst.Med.Immunology, Charité, Director of the Berlin-Brandenburg Center for Regerative Therapies (BCRT) and Deputy Speaker of the Berlin-Brandenburg School for Regenerative Therapies (BSRT) –DFG Graduate School. He published more than 50 patents and is PI or at the steering committees of several collaborative research projects as : Adoptive T cell therapy TR 36 (DFG, 2009),Suppression of undesired immune reaction SFB 650 (DFG, 2013), BioDrIm (EU, 2012), The One Study (EU, 2010), BSRT Graduate School (DFG, 2008), TCR Sequences (IBB, 2010). In 2008, he obtained W3 professorship on Immunology and Regeneration, Charité, HUB.